Rik Joos

1.1k total citations
20 papers, 453 citations indexed

About

Rik Joos is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Rik Joos has authored 20 papers receiving a total of 453 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 10 papers in Hematology and 6 papers in Immunology. Recurrent topics in Rik Joos's work include Autoimmune and Inflammatory Disorders Research (9 papers), Spondyloarthritis Studies and Treatments (7 papers) and Psoriasis: Treatment and Pathogenesis (5 papers). Rik Joos is often cited by papers focused on Autoimmune and Inflammatory Disorders Research (9 papers), Spondyloarthritis Studies and Treatments (7 papers) and Psoriasis: Treatment and Pathogenesis (5 papers). Rik Joos collaborates with scholars based in Belgium, United States and United Kingdom. Rik Joos's co-authors include Georg Schett, J. Rodrigues, Adele R. Vessey, Randall M. Stevens, Herman Mielants, J. Wollenhaupt, Kim Papp, ChiaChi Hu, De Vos M and Veys Em and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Arthritis & Rheumatology.

In The Last Decade

Rik Joos

18 papers receiving 431 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rik Joos Belgium 11 266 212 149 81 58 20 453
Khaled Alsaeid Kuwait 14 191 0.7× 118 0.6× 56 0.4× 51 0.6× 55 0.9× 34 431
H Zeidler Germany 12 507 1.9× 217 1.0× 135 0.9× 38 0.5× 32 0.6× 36 645
Ramanand A. Subramanian United States 12 257 1.0× 296 1.4× 171 1.1× 22 0.3× 66 1.1× 20 565
Ivet Etchegaray‐Morales Mexico 13 342 1.3× 174 0.8× 50 0.3× 110 1.4× 51 0.9× 62 534
Silvia Vignola Italy 15 96 0.4× 197 0.9× 118 0.8× 30 0.4× 97 1.7× 27 519
H H Chng Singapore 9 265 1.0× 164 0.8× 40 0.3× 62 0.8× 11 0.2× 14 398
Panagiotis Trontzas Greece 9 248 0.9× 108 0.5× 82 0.6× 33 0.4× 55 0.9× 11 421
Waraporn Sukitawut Thailand 15 208 0.8× 128 0.6× 26 0.2× 89 1.1× 29 0.5× 26 358
Nicola Farina Italy 13 128 0.5× 86 0.4× 65 0.4× 30 0.4× 72 1.2× 30 459

Countries citing papers authored by Rik Joos

Since Specialization
Citations

This map shows the geographic impact of Rik Joos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rik Joos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rik Joos more than expected).

Fields of papers citing papers by Rik Joos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rik Joos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rik Joos. The network helps show where Rik Joos may publish in the future.

Co-authorship network of co-authors of Rik Joos

This figure shows the co-authorship network connecting the top 25 collaborators of Rik Joos. A scholar is included among the top collaborators of Rik Joos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rik Joos. Rik Joos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dorpe, Jo Van, Isabelle Peene, Karin Melsens, et al.. (2025). Endogenous Lipoid Pneumonia in Adult Autoinflammatory Disease. Arthritis Care & Research. 77(10). 1184–1193.
2.
Sabato, Vito, et al.. (2022). Successful Rituximab Therapy for Pediatric Antiphospholipid-Related Chorea: A Case Report and Review of the Literature. Neuropediatrics. 53(5). 366–369. 1 indexed citations
3.
Vlam, Kurt de, Serge Steinfeld, A. Nzeusseu Toukap, et al.. (2021). The burden of psoriatic arthritis in the biologics era: data from the Belgian Epidemiological Psoriatic Arthritis Study. Lara D. Veeken. 60(12). 5677–5685. 12 indexed citations
4.
Hsu, Joy, Wendy Douglass, Chris Wells, et al.. (2019). Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatric Rheumatology. 17(1). 57–57. 19 indexed citations
5.
Cuttica, R, Hans‐Iko Huppertz, Rik Joos, et al.. (2018). THU0598 Safety of tocilizumab in patients aged <2 years with active systemic juvenile idiopathic arthritis treated for one year. Annals of the Rheumatic Diseases. 77. 499–499. 1 indexed citations
6.
Hsu, Joyce, Christine L. Wells, R Cuttica, et al.. (2017). OP0197 Evaluation of a dosing regimen for tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases. 76. 133–133. 1 indexed citations
7.
Vlam, Kurt de, Rik Lories, Serge Steinfeld, et al.. (2016). AB0737 Clinical Axial Involvement in Patients with Psoriatic Arthritis Is Underestimated: Impact on Burden of The Disease. Data from The Bepas Cohort. Annals of the Rheumatic Diseases. 75. 1156–1157. 1 indexed citations
8.
Vlam, Kurt de, Rik Lories, Serge Steinfeld, et al.. (2016). FRI0462 Gender Differences in The Disease Expression and Articular Manifestations among Patients with Psoriatic Arthritis. Data from The Bepas Cohort. Annals of the Rheumatic Diseases. 75. 604–605. 1 indexed citations
9.
Benedetti, Fabrizio De, Nadina Rubio‐Pérez, Steven I. Goodman, et al.. (2014). A45: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis. Arthritis & Rheumatology. 66(S3). 6 indexed citations
10.
Schett, Georg, J. Wollenhaupt, Kim Papp, et al.. (2012). Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled study. Arthritis & Rheumatism. 64(10). 3156–3167. 162 indexed citations
11.
Schett, Georg, J. Wollenhaupt, Kim Papp, et al.. (2012). Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis & Rheumatism. n/a–n/a. 14 indexed citations
12.
Dewint, Pieter, Ilse Hoffman, Sven Rogge, et al.. (2005). Effect of age on prevalence of anticitrullinated protein/peptide antibodies in polyarticular juvenile idiopathic arthritis. Lara D. Veeken. 45(2). 204–208. 17 indexed citations
13.
Foeldvari, Ivan, Nina Birdi, Rubén Cuttica, et al.. (2000). Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi‐national survey. Lara D. Veeken. 39(5). 556–559. 60 indexed citations
14.
Keyser, Filip De, et al.. (2000). Occurrence of scleroderma in monozygotic twins.. PubMed. 27(9). 2267–9. 13 indexed citations
15.
Joos, Rik, et al.. (1987). Gold- induced aplastic anemia. Clinical Rheumatology. 6(4). 600–605. 10 indexed citations
16.
Mielants, Herman, Veys Em, Rik Joos, Claude Cuvelier, & De Vos M. (1987). Repeat ileocolonoscopy in reactive arthritis.. PubMed. 14(3). 456–8. 36 indexed citations
17.
Mielants, Herman, et al.. (1987). Late onset pauciarticular juvenile chronic arthritis: relation to gut inflammation.. PubMed. 14(3). 459–65. 27 indexed citations
18.
Mielants, Herman, Veys Em, Rik Joos, et al.. (1987). HLA antigens in seronegative spondylarthropathies. Reactive arthritis and arthritis in ankylosing spondylitis: relation to gut inflammation.. PubMed. 14(3). 466–71. 39 indexed citations
19.
Mielants, Herman, et al.. (1986). Familial aggregation in seronegative spondyloarthritis of enterogenic origin. A family study.. PubMed. 13(1). 126–8. 10 indexed citations
20.
Joos, Rik, et al.. (1984). Plasma concentrations of nifedipine in patients with renal failure.. PubMed. 34(3). 307–8. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Khaled Alsaeid Breakdown of academic impact, for papers by H Zeidler Breakdown of academic impact, for papers by Ramanand A. Subramanian Breakdown of academic impact, for papers by Ivet Etchegaray‐Morales Breakdown of academic impact, for papers by Silvia Vignola Breakdown of academic impact, for papers by H H Chng Breakdown of academic impact, for papers by Panagiotis Trontzas Breakdown of academic impact, for papers by Waraporn Sukitawut Breakdown of academic impact, for papers by Nicola Farina
Rankless by CCL
2026